Calamos Advisors’s Guardant Health GH Stock Holding History

Calamos Advisors’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.19M	Sell	47,940 -2,728	-5%	-$297K	0.02%	491
2026 Q1	$4.68M	Sell	50,668 -5,800	-10%	-$582K	0.02%	570
2025 Q4	$5.77M	Buy	56,468 +11,968	+27%	+$1.07M	0.02%	505
2025 Q3	$2.78M	Buy	+44,500	New	+$2.42M	0.01%	603

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Calamos Advisors's GH Position: Q2 2026 in Review

Calamos Advisors reduced its Guardant Health (GH) stake by 5.4% in Q2 2026, selling an estimated $297K and leaving 47,940 shares worth $7.19M. The position accounts for 0.02% of the portfolio, ranked #491.

Calamos Advisors first reported a position in GH in Q3 2025 and has held it in 4 quarters since. 598 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Calamos Advisors held 47,940 shares of Guardant Health worth $7.19M as of Q2 2026.
Calamos Advisors sold 2,728 Guardant Health shares in Q2 2026, an estimated $297K.
Guardant Health made up 0.02% of Calamos Advisors's portfolio in Q2 2026, its #491 holding.
Calamos Advisors first reported a position in Guardant Health in Q3 2025 and has held it in 4 quarters since.
598 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.